Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 42Lymphoma 33Melanoma 32Breast Neoplasms 31Leukemia, Myeloid, Acute 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia, Lymphocytic, Chronic, B-Cell 23Lymphoma, Non-Hodgkin 22Multiple Myeloma 21Lymphoma, Follicular 21Myelodysplastic Syndromes 19Prostatic Neoplasms 18Neuroblastoma 18Lymphoma, Mantle-Cell 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myeloid, Chronic-Phase 16Hodgkin Disease 15Neoplasms, Plasma Cell 14Lymphoma, Large-Cell, Immunoblastic 14Ovarian Neoplasms 13Lung Neoplasms 13Congenital Abnormalities 13Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Accelerated Phase 12Carcinoma, Non-Small-Cell Lung 12Burkitt Lymphoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Glioblastoma 11Carcinoma, Ovarian Epithelial 11Colorectal Neoplasms 10

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × sargramostim × Clear all
NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡